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Summary 
The cap3B gene, which is involved in the formation of the capsule of Streptococcus pneumoniae 
type 3, encodes a 49-kD protein that has been identified as a polysaccharide synthase. Escheri- 
chia coli cells harboring the recombinant plasmid pTBP3 (cap3B) produced pneumococcal type 
3 polysaccharide, as demonstrated by immunological tests.  Biochemical and cell fractionation 
analyses revealed that this polysaccharide had a high molecular mass and was localized in sub- 
stantial  amounts in the periplasmic space orE. coli. Unencapsulated ($2-), laboratory pneumo- 
coccal strains  synthesized type 3 polysaccharide by transformation with plasmid pLSE3B har- 
boring cap3B.  In addition, encapsulated pneumococci of types 1, 2, 5,  or 8 transformed with 
pLSE3B can direct the synthesis  ofpneumococcal type 3 polysaccharide, leading to the forma- 
tion of strains that display binary type of capsule. 
C 
apsular polysaccharide protects bacteria from phago- 
cytosis by polymorphonuclear leukocytes, and the vir- 
ulence of Streptococcus pneumoniae  is determined by the size 
and the chemical composition of the capsule (1). 90 differ- 
ent capsular types of S. pneumoniae  have been described (2) 
and variations in capsular serotype by in vivo and in vitro 
experiments led to the identification of DNA as the "tram- 
forming principle" (3, 4). The importance of these types of 
genetic exchanges in nature has recently been suggested as 
a source of variation of the different pneumococcal strains 
to expand their capacity of colonizing the host organism (5). 
Type  3  pneumococci produce  a  capsule  composed  of 
cellobiuronic acid units connected in a [3(1-+3) linkage (6). 
Cellobiuronic acid is a disaccharide consisting of D-glucu- 
ronic acid (GlcA) 1 [3(1-+4)  linked to D-glucose (Glc). Re- 
cently, the  genes implicated in  the biosynthesis of type 3 
capsular polysaccharide have been cloned and some of them 
have been partially characterized (7-12). At least three type 
3-specific genes have been found, namely, cap3A,  B, and C 
(also designated as cps3D,  S  and  U,  respectively). Genetic 
and biochemical analyses showed that Cap3A is a UDP-Glc 
dehydrogenase that converts UDP-Glc into UDP-GlcA (8, 
12), whereas cap3  C complements the galU defect of Escherichia 
coli and, therefore, codes for a UDP-Glc pyrophosphorylase 
(11).  On  the  other hand,  sequence comparison suggested 
that cap3B might code for the  type-specific polysaccharide 
synthase, although a precise settlement could not be reached 
~Abbreviations used in  this paper: Glc, glucose; GlcA, glucuronic acid; 
IPTG, isopropyl-[3-D-thiogalactopyranoside. 
at that moment. The genes cap3A,  B, and C are transcribed 
together,  and  insertion-duplication  mutagenesis  revealed 
that cap3C is not essential  for capsule formation (11).  Clas- 
sical genetic studies ofpneumococcal capsular type 3 strains 
suggested that all but one of the spontaneous mutations that 
alter the formation of type 3 polysaccharide were located in 
cap3A  (13).  Several cap3A  point mutations have now been 
characterized,  and  some  of them  completely blocked the 
synthesis of type 3  polysaccharide (8,  10),  whereas only a 
deletion affecting simultaneously cap3A  and cap3B  (13)  or 
insertion mutations (10) affecting cap3B have been reported 
so  far.  Since polar effects are  likely to  occur as  a  conse- 
quence of plasrnid  or transposon insertion, a definite con- 
clusion on the role of Cap3B on capsular biosynthesis still 
awaited  the  isolation  and  characterization of cap3B  point 
mutants. 
In this communication, we report the isolation and char- 
acterization ofa cap3B mutant. We also show that Cap3B is 
a synthase that led to the synthesis of type 3 pneumococcal 
polysaccharide of high molecular mass in E.  roll, and that 
was  sufficient to  produce  binary  capsulated  strains  when 
cloned into several S.  pneumoniae  encapsulated strains  be- 
longing to several serotypes. 
Materials  and Methods 
Bacterial Strains, Plasmids  and Growth Conditions.  The type 3 S. 
pneumoniae strain 406  has  been  described  elsewhere  (7). The 
pneumococcal strain M25, a type 1 encapsulated derivative of the 
laboratory strain M24  (7), was constructed  by M.  Mollerach in 
our laboratory by transformation with DNA from a type 1 clini- 
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clinical isolates belonging to serotypes 2 (15783/94), 5 (8595/95), 
and 8 (6028), and were provided by A. Fenoll from the Spanish 
Reference Laboratory  for Pneumococci (Instituto de Salud Car- 
los  III, Majadahonda,  Madrid).  The  unencapsulated $3-  strain 
NP,.3-10  is  a  spontaneous nmtant of the  pneumococcal strain 
NS3-1 (8), isolated as described elsewhere in detail (7). Two non- 
encapsulated  ($2-) mutants used in some  experiments were the 
laboratory  strains Mll and M31  (14). These strains were late de- 
scendants  of the  strain  R36A  (4).  S.  pneumoniae  strains  were 
grown in liquid C+Y medium (7)  or on reconstituted tryptose 
blood agar base plates  (Difco Laboratories,  Detroit, MI) supple- 
mented with 5% (vol/vol) defibrinated sheep  blood. Serotyping 
was carried out by the "Quellung" reaction with type-specific anti- 
sera purchased from the Staten Seruminstitut (Copenhagen, Den- 
mark) (15). The same antisera were used for other immunological 
techniques (see below). E. coli strains BL21(DE3)  (16), C600 (17), 
and DH10B  (F'  mcrA A(mrr  hsdRMS-mcrBC)  ~80dlacZA  M15 
AlacX74  deoR  recAl  araD139  A(ara-leu)7697  galU galK X-  rpsL 
endA I nupG)  (Life Technologies) were used as hosts for recombi- 
nant plasmids and grown in LB medimn (17). Plasmids pLysS (16), 
pT7-7 (18), pLSE1 (19), and pKEP,2,  pKER22, and pKEP,23  (8) 
have been already described. 
DNA  Manipulation,  Plasmid Construction, and  Genetic Transfor- 
mation.  Preparation of plasmid DNA, digestion  with restriction 
endonucleases,  ligation reactions,  and agarose gel electrophoresis 
followed  standard  procedures  (17). PCR amplification of cap3B 
was performed by using 2  U  of Taq polymerase  (Perkin-Elmer 
Cetus Corp., Norwalk, CT), 10 ng ofplasmid pKER2, 1 I~M of 
each synthetic oligonucleotide primer, 250  bLM of each  dNTP, 
and 5  mM  MgC12 in the  buffer recommended by  the  manu- 
facturers. Amplification was achieved with a cycle of 3 rain dena- 
turation at 95~  2 min annealing at 69~  and 5 rain polymerase 
extension at 72~  repeated 40 times with a final 6-rain extension 
at 72~  and slow cooling to 4~  with a Gene ATAQ controller 
(Pharmacia LKI~, Piscataway, NJ). The following synthetic oligo- 
nucleotides were  used:  PCAP3B  (5'-CTATACACGCGATT- 
CATATGGCAGAG-3')  and PCAP21  (5'-GTGTGCCCAGCC- 
CTGCAGC-3'); the  underlined sequence  indicates  restriction 
site for NdeI. Transformation of competent cells of S. pneumoniae 
(19)  and E.  coli (17) have  been described.  Before  addition of 
transforming DNA, clinical isolates of S. pneumoniae were incu- 
bated with a crude preparation of competence factor,  as previ- 
ously reported  (20). Transformants of S.  pneumoniae and E.  coil 
obtained with  plasnfids derived from  pLSE1 were  selected  by 
plating with lincomycin (1  txg/ml),  or erythromycin (500  I~g/ 
ml), respectively.  When pT7-7 or its derivative  pTBP3 (see be- 
low)  were used as donor DNAs, E.  coli BL21(DE3)pLysS  trans- 
formants were scored on LB agar plates containing  chlorampheni- 
col (20 ~g/ml) and ampicillin (75  btg/ml). DNA sequencing was 
carried out with appropriate  oligonucleotides with an Abi Prism 
377 DNA Sequencer (Perkin-Elmer Cetus). 
Characterization of Capsular Polysaccharide.  Highly purified pneu- 
mococcal polysaccharides  were prepared essentially  as described else- 
where  (15). Briefly,  exponentially growing cultures  of S.  pneu- 
moniae in C+Y n~edium were lysed by the addition of 1% sodium 
deoxycholate  (final concentration) and incubation at 37~  for 30 
rain. When lytA mutants were used, cells were incubated with 5 
p~g/ml of LytA pneumococcal autolysin (6  ￿  1()  ~ U/mg) for 30 
miu at 37~  before the addition of sodium deoxycholate.  The ly- 
sate was acidified with acetic acid (0.5% final concentration) and 
heated  to boiling point. After  cooling, the mixture was neutral- 
ized with NaOH and deproteinized with chloroform/isoamyl al- 
cohol (24:1). The polysaccharide was precipitated  by adding 2 vol 
of cold absolute ethanol. After standing overnight at 4~  the pre- 
cipitate  was recovered by centrifugation (10,000 g for  30  rain), 
washed  once with 96%  ethanol, twice  with diethyl ether,  and 
dried at 65~  The polysaccharide was dissolved in distilled water 
and deproteinized again twice with phenol/chloroform/isoamyl 
alcohol  (25:24:1) and once more with chloroform/isoamyl alco- 
hol. Afterwards, the aqueous phase received sodium acetate (final 
concentration =  5%), and  the  polysaccharide  was  precipitated 
with half its volume of isopropanol.  After standing overnight at 
4~  the  polysaccharide  was  washed  as  described  above,  dried, 
and dissolved in distilled water.  For rapid,  crude preparations  of 
pneumococcal polysaccharides, 1.5 ml of late exponentially grow- 
ing cultures of S. p~ieumoniae were treated as described above, ex- 
cept that the deproteinization step was excluded,  and the polysac- 
charide  was  precipitated  only once  with  absolute  ethanol  and 
dissolved in 100 I~1 of distilled water. 
The uronic acid content of the purified type 3 polysaccharide 
was measured by the carbazole assay (21) with glucuronic acid as 
the standard. The mass of the polymers was determined by gel fil- 
tration (22) with Sepharose CL-4B (Pharmacia Biotech, Uppsala, 
Sweden). Double-diffusion  experiments were performed on 0.7% 
agarose-coated  microscope slides as previously described  (23). To 
estimate the amount of type 3 polysaccharide present in a sample, 
5 btl of serial dilutions of the extract and known amounts of puri- 
fied polysaccharide were analyzed by immunodiffusion  against 5 btl 
of the same batch of type 3 antiserum. In these experimental con- 
ditions, 0.25  ~g of type 3 polysaccharide is enough to give a tiny 
but still visible precipitation band after overnight incubation. 
Miscellaneous Techniques.  SDS-PAGE was  carried  out  as  de- 
scribed by Laemmli (24). After SDS-PAGE, proteins were blotted 
onto a polyvinylidene dittuoride membrane (Immobilon-pSQ; Milli- 
pore Corp., Bedford,  MA), and stained briefly with amido black 
(Sigma Immunochemicals, St. Louis, MO). Subsequently, the de- 
sired band was cut and the NH2-terminal amino acid sequence 
was detemfined as described elsewhere (25). Preparation ofsphero- 
plasts and fractionation of E.  coli cells were carried  out as previ- 
ously described  (26). 
Results 
cap3B Is hwolved in Capsular Biosynthesis.  We  reported 
previously the isolation of 12 spontaneous $3-  strains that 
were characterized as cap3A  nmtants on the basis of trans- 
formation  to  the  smooth  phenotype  with  the  wild-type 
cap3A gene (8).  In a subsequent round of isolation of rough 
mutants, however,  one of them  (strain NP,3-10)  was  not 
transformed  to  the  $3 +  phenotype by  the  cap3A +  allele, 
and  was  studied  in  detail.  When  the  cap3B  gene  of the 
wild-type strain 406  was  amplified by  PCR  and  used  to 
transform competent NR.3-10 cells,  fully capsulated trans- 
formants were  obtained (Fig.  1).  The  mutation could be 
mapped  more  accurately  by  transformation  experiments 
with different restriction fragnnents of cap3B.  Sequence anal- 
ysis of the PCR.-amplified cap3B allele of NR3-10 revealed 
the insertion of an additional single base (T) in a preexistent 
run of six T's and close to the 5' end of the wild-type gene, 
causing  the  appearance  of  a  termination  codon  (TAA) 
some 50  nucleotides downstream of the insertion. To ex- 
clude  the  possibility of an  artifact  introduced during the 
PCR amplification, several PC1K rounds were carried out, 
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Figure  1.  Partial  restriction map, genetic organiza- 
tion of the cap3ABC operon, and characterization of 
the NR3-10 cap3B mutant strain. (A) Only those re- 
striction sites that are pertinent to this work are indi- 
cated. A, Accl; H, HindlII; M, Munl; P,  Pvull; Ps, 
PstI; S, ScaI. Triangles  indicate the location and direc- 
tion of the oligonucleotide  primers PCAP3B (1~) and 
PCAP21 (D). (B) Transformation  experiments to the 
capsulated $3 +  phenotype. Competent  cells of the 
cap3B mutant (NR3-10) were incubated with DNA 
fragments, either PCR amplified or isolated from an 
agarose gel after digestion with a restriction endonu- 
clease (open bars) or plasmids. Formation (or not) of $3 + 
transfonnants  is indicated  by +  (or -). (C) The nucle- 
otide sequence  of the relevant region of the cap3B  + al- 
lele (strain 406) and of the mutant NR3-10  are indi- 
cated. Numbers in parenthesis indicate the nudeotide 
position taking as +1 the first nucleotide of the ATG 
start codon of the cap3B  gene (11). 
and the  corresponding products were sequenced. In addi- 
tion,  the  sequence previously reported  for  the  wild-type 
gene (11) was fully confirmed by direct sequencing of the 
PCR-amplified cap3B gene of the 406 strain. These results 
taken  together  demonstrated that  Cap3B  directly partici- 
pates in the synthesis of type 3 pneumococcal polysaccharide. 
The frameshifting that originated in the strain NR3-10 
should cause the synthesis of a truncated, and possibly inac- 
tive,  Cap3B  protein.  Nevertheless,  a  closer inspection of 
NR3-10 revealed the presence of a small amount of type 3 
capsular polysaccharide (~-,10%  of that found in the wild- 
type strain; not shown). This finding might be explained as 
the result of the slippage of one nucleotide during transla- 
tion  of the  mRNA  of the  mutant strain,  as  already  de- 
scribed for several genes in other species (27). 
Cloning and Expression of cap3B in E. coli.  Several  groups 
have  experienced severe  difficulties in  cloning the  func- 
tional pneumococcal genes in E. coli. In particular, expres- 
sion of cap3B in E.  coli was lethal to  the host and, conse- 
quently,  characterization  of  the  enzyme  could  not  be 
achieved  (10).  To  overcome  this  problem,  we  tried  to 
clone  cap3B  under  the  control  of  the  T7  promoter  as 
shown in Fig. 2. In short, a DNA fragment containing cap3B 
was amplified by PCR using plasmid pKER2 and the oli- 
gonucleotides PCAP3B and PCAP21  as primers. After di- 
gestion with  NdeI  (a  target  site  engineered in PCAP3B) 
and PstI,  the  cap3B gene was ligated to  pT7-7 previously 
digested with the same enzymes, introduced by transforma- 
tion  into  E.  coli DH10B,  and  the  recombinant plasmid 
pTBP3 was isolated from one chloramphenicol/ampicillin- 
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Figure 2.  Schematic  representation  of the expression 
plasmids pTBP3 and pLSE3B. Triangles  represent the 
location and orientation of the oligonucleotides  prim- 
ers, as described in the legend to Fig. 1. The PCAP3B 
primer  includes the  NdeI  (N)  restriction  site. E, 
EcoP,  l; H, HindlII; P, PvulI; Ps, Pstl. bla, Em and Tc 
represent the genes encoding the ampicillin-, erythro- 
mycin/lincomycin-, and tetracycline-resistance  traits, 
respectively (19). (t)10 indicates the promoter of the 
gene 10  of T7 bacteriophage recognized by the T7 
RNA polymerase. 
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pLysS. The presence ofpLysS was an absolute requirement 
for  successful  transformation  with  pTBP3,  since  prelimi- 
nary  experiments  using  the  E.  coli strain  BL21(DE3)  did 
not yield any transformants  (not  shown).  To  clone  cap3B 
into pLSE1,  a plasmid  able  to replicate both in E.  coli and 
S.  pneumoniae  (19),  the  2-kb  PvulI/HindlII  fragment  of 
pKER2  was  ligated  to  pLSE1  previously  digested  with 
EcoRV  and  HindlII  (Fig.  2).  The  ligation  mixture  was 
used  to  transform  E.  coli C600,  and pLSE3B was  selected 
by  screening  among  the  erythromycin-resistant  transfor- 
mants.  It was expected  that  expression  of cap3B would be 
under the control of the tetracycline promoter of the vec- 
tor plasmid,  as it has been reported for other genes (28 and 
references therein). 
For T7  expression,  E.  coli cells  harboring pTBP3  were 
grown in LB medium up  to an OD600  of 0.6 and induced 
with isopropyl-IB-D-thiogatactopyranoside (IPTG;  1 mM). 
A  49-kD  protein,  corresponding  to  the  expected  size  of 
Cap3B  (11),  was  observed  after  a  90-rain  induction,  as 
shown by SDS-PAGE of cellular crude extracts  (Fig. 3 A). 
This band was cut from the  gel,  and determination  of the 
NH2-terminal amino acid sequence yielded Met-Tyr-Thr- 
Phe-Ile-Leu,  thus  confirming the  sequence  deduced  from 
the nucleotide analysis of the cap3B gene (11). Control cells 
containing  pT7-7  did  not  show  any  additional  protein 
band over a 3-h time course experiment. 
Synthesis  and Analysis  of the  Pneumococcal Type  3  Polysac- 
charide in E. coli.  Sonicated  extracts  prepared  from  both 
induced and uninduced cultures of E. coli BL21  (DE3)pLysS 
harboring pTBP3 contained type 3 polysaccharide, as dem- 
onstrated  by immunoprecipitation  with a  type-specific an- 
tiserum  (Fig.  3  B).  The  amount  of type  3  polysaccharide 
found in uninduced E.  coli cells  was  10-25% of that of in- 
duced cultures.  This result is in agreement with an incom- 
plete repression  of the T7 promoter in the host strain used 
here,  as it has been reported previously (16).  On the other 
hand, IPTG-induced E. coli cultures synthesized as much as 
1-5%  of the  amount  of type  3  polysaccharide synthesized 
by S. pneumoniae (between  10 and 50 ~g per  108 cells;  our 
unpublished  results).  Uninduced  E.  coli cultures  harboring 
pTBP3 were used to determine  the subcellular localization 
of the  pneumococcal polysaccharide.  It was  found  that  a 
substantial  amount  (~40%)  of the  type  3  polysaccharide 
was  localized  in  the  periplasmic  space  of E.  coli, 40-50% 
was in the  cytoplasm,  and the rest were in  the  membrane 
fraction (not shown). This polysaccharide was further char- 
acterized by gel filtration chromatography, showing it to be 
highly polymerized  as  it  eluted  in  the  void  volume  of a 
Sepharose  CL-4B column (not shown).  These results indi- 
cated that Cap3B is actually the enzyme that synthesizes the 
type 3 pneumococcal polysaccharide. 
Formation  of Binary Cells of Pneumococcus by  Transformation 
with the cap3B Gene.  Pneumococcal  strains  that  produce 
simultaneously  two  distinct  capsular  polysaccharides  have 
been  described  previously (see  reference  29  for a  review). 
These  strains  arise  by  transformation  reactions  between 
pneumococci-expressing  capsules  that  contain  hexuronic 
acids,  such as those belonging to serotypes  1 and 3. When 
the plasmid pLSE3B was introduced by transformation into 
the $1  pneumococcal strain M25,  all the lincomycin-resis- 
rant transformants expressed both type  1 and type 3  capsu- 
lar polysaccharides, as determined by the Quellung reaction 
(data not shown), as well as by immunodiffusion analysis of 
Figure 3.  Expression  of  the Cap3B polysaccharide  synthase and synthe- 
sis of type 3 pneumococcal polysaccharide by E. coli containing the re- 
combinant plasmid pTBP3. (A), BL21(DE3)pLysS  cells containing either 
pTBP3 or pT7-7 vector alone were grown to an OD600 of 0.6, induced 
with l mM IPTG, and the crude sonicated extracts were analyzed  by 10% 
by SDS-PAGE. Lane 1, extracts from bacteria containing pT7-7. Lanes 2 
and 3, extracts from bacteria harboring pTBP3 and removed before in- 
duction with IPTG and after 90 rain induction, respectively. The location 
of the overexpressed Cap3B is indicated by an arrow. The molecular mass 
of  the standards are indicated on the left. (B), Double immunodiffusion  test. 
Wells labeled 1-3 contain extracts corresponding  to samples 1-3 of  A, re- 
spectively. Well 4 contains purified type 3 pneumococcal polysaccharide. 
The center well received type 3 antiserum. Each well received 10 Ixl of 
the corresponding  sample. 
Figure 4.  Double  immunodiffusion in agarose of capsulated pneumo- 
cocci, l-5indicate  antisera against pneumococcal  polysaccharides  of  types 
1-3, 5, and 8, respectively. A-E designate capsular polysaccharides  puri- 
fied from the S. pneumoniae  strains ofserotypes 1-3, 5, and 8, respectively. 
a-d correspond to binary transformants of the following serotypes: 1/3, 
2/3, 5/3, and 8/3,  respectively, e and f contains polysaccharide prepared 
from $3 + transforrnants of Mll  and M31, respectively. Each well re- 
ceived 10 ~tl of  the corresponding  sample. 
452  Type 3 Pneumococcal Polysaccharide Synthase cell extracts with specific antisera (Fig.  4).  This result was 
not restricted to serotypes 1 and 3 because pneumococcal 
cells belonging to serotypes 2, 5, and 8, all of them produc- 
ing capsules  that contain glucuronic acid (30), also gave rise 
to binary transformants when  transformed with  pLSE3B. 
Furthermore,  strains  Mll  and  M31,  two  $2-  laboratory 
derivatives of the rough strain R36A, also synthesized type 
3 capsule (but not type 2) when transformed with pLSE3B 
(Fig. 4). In every case, the type 3 polysaccharide produced 
was  of high  Mr,  as  demonstrated  by  gel  filtration  (not 
shown). 
Discussion 
The molecular organization of the  genes implicated in 
capsulation of S. pneumoniae is currently being studied. As 
in Gram-negative bacteria (31),  genes involved in the syn- 
thesis  of the sugar precursors and the polymerization reac- 
tions appear to be specific for any given capsular type also 
in S. pneumoniae (7-12, 32). Type 3--specific  genes are ar- 
ranged as an operon, and the promoter is located just up- 
stream of the first specific gene (cap3A) (11).  In type 19F, 
however, Guidolin and co-workers (32) suggested that up- 
stream  of the  type-specific genes,  the  transcript  included 
several open reading frames common to all pneumococci. 
Thus, it appears that diverse functional organizations of the 
capsular genes may exist in  different pneumococcal sero- 
types. 
Very few gene products thought to be implicated in cap- 
sule formation in Gram-positive bacteria have been identi- 
fied  biochemically so  far.  Among  these,  the  S.  pyogenes 
hasA codes for an enzyme that directs hyaluronic acid bio- 
synthesis,  the  component of the  capsule  of this  microor- 
ganism  (33-35).  It has been shown that HasA is necessary 
and sufficient to synthesize hyaluronic acid both in Entero- 
coccusfaecalis and in E. coli, provided that the host bacterium 
produces the corresponding sugar nucleotides (UDP-GlcA 
and  UDP-N-acetyl  glucosamine)  (36).  This  relationship 
appears  also  to be  the  case  for the pneumococcal Cap3B 
synthase (Fig.  3 B).  In addition to the omnipresent UDP- 
Glc, which plays  a central role in the biosynthesis of most 
cellular polysaccharides, UDP-GlcA has  been found both 
in E. coli (37-39) and in some S. pneumoniae serotypes (40). 
Since type  1 capsule contains galacturonic acid, a specific 
epimerase  reaction  is  required  to  convert UDP-GlcA  to 
UDP-GalA  (41).  Furthermore, since pTBP3 and pLSE3B 
contain exclusively the cap3B gene as an insert (Fig. 2), it is 
clear  that  the  Cap3B  synthase  has  both  UDP-Glc  and 
UDP-GlcA  glycosyltransferase activities and possibly syn- 
thesizes the type 3  polysaccharide in a processive manner 
by monomer addition.  In S. pyogenes, Dougherty and van 
de  Rijn  (34)  speculated that  HasA synthase may catalyze 
transfer  of only  one  of the  two  sugars,  N-acetyl  glu- 
cosamine, to the nascent hyaluronic acid chain. Neverthe- 
less, DeAngelis and Weigel  (35)  concluded that HasA is a 
synthase  that  possesses  both  glycosyl transferase  activities 
that are required to polymerize hyaluronic acid. 
In E. coli and in other capsulated Gram-negative bacteria, 
the  capsular  polysaccharide determinants  were  shown  to 
contain  three  phenotypically  distinct  regions  associated 
with polysaccharide expression. Region  1 is necessary for 
the transport of mature, lipid-linked polysaccharide across 
the outer membrane and its  assembly into a capsule.  Re- 
gion 2  is serotype specific and codes for the  enzymes in- 
volved in  synthesis  and  polymerization.  Region  3  is  re- 
sponsible for the translocation of the polysaccharide across 
the cytoplasmic membrane (42). The KpsMT proteins coded 
by genes located in region 3 and belonging to the family of 
ABC transporters (43) are capable of transporting a variety 
of acidic polysaccharides to the periplasm. Of particular in- 
terest is the finding reported here that ~50% of the pneu- 
mococcal type 3  polysaccharide synthesized in E.  coli ap- 
pears  in  the  periplasmic  space,  although  we  can  not 
determine whether the mechanism for this transport is the 
same as that for the homologous polysaccharide. 
In Gram-positive bacteria, the mechanism ofpolysaccha- 
ride transport has not been characterized so far. In type 19F 
pneumococci, it has been suggested that some of the genes 
located upstream  of the  specific capsular  cluster  (namely, 
cps 19fA-D) might be responsible for the transport of the in- 
tracellularly synthesized capsular polysaccharide (32). How- 
ever, we have recently shown that the genes corresponding 
to those described by Guidolin et al. are not functional in 
pneumococci belonging to the type 3  serotype (11).  The 
results  reported  here  strongly  suggest  that  another  still- 
unknown mechanism may be responsible for the export of 
the capsular polysaccharide through the cytoplasmic mem- 
brane. 
We have shown that the presence of the type 3 pneumo- 
coccal  polysaccharide  synthase  is  sufficient  to  direct  the 
synthesis  of a  type 3  capsule  in  S.  pneumoniae strains  be- 
longing to serotypes 1,  2,  5,  and 8  (Fig.  4).  It can be as- 
sumed that  the mechanism  of polysaccharide transport of 
the recipient cell is used for the formation of a type 3 cap- 
sule  in  the  binary  transformants.  Early experimental evi- 
dence showed that when an unencapsulated mutant of type 
3 is transformed with DNA from a capsulated strain of type 
1, a minority (2-5%)  of the transformants were of the bi- 
nary type, i.e., they reacted with both types 1 and 3 antisera 
and synthesized two distinct polysaccharides (44). Transfor- 
mation  experiments  with  these  stable  binary  strains  sug- 
gested that a supernumerary gene cluster (i.e., type 1) had 
been inserted, presumably by homologous recombination, 
at a repeat element unlinked to the capsule locus (reviewed 
in 29). Recently, we have shown that copies of the DNA 
sequences  located  upstream  of the  cap3ABC  operon  are 
present in different locations in the genome (8). In contrast 
with  this  situation,  the  transformants  described  here  re- 
suited  from  the  expression  of the  plasmid-borne  cap3B 
gene. In conclusion, provided that the corresponding sugar 
nucleotide precursors (UDP-Glc and UDP-GlcA) are present, 
cap3B appears to be the only gene required to direct type 3 
polysaccharide biosynthesis in the pneumococcal strains  or 
in E. coli. 
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